369 related articles for article (PubMed ID: 29056426)
41. Arginase-II activates mTORC1 through myosin-1b in vascular cell senescence and apoptosis.
Yu Y; Xiong Y; Montani JP; Yang Z; Ming XF
Cell Death Dis; 2018 Feb; 9(3):313. PubMed ID: 29472548
[TBL] [Abstract][Full Text] [Related]
42. mTORC1 Activity in Psoriatic Lesions Is Mediated by Aberrant Regulation through the Tuberous Sclerosis Complex.
Ferreri A; Lang V; Kaufmann R; Buerger C
Cells; 2022 Sep; 11(18):. PubMed ID: 36139422
[TBL] [Abstract][Full Text] [Related]
43. Amino Acid Transporters Are a Vital Focal Point in the Control of mTORC1 Signaling and Cancer.
Cormerais Y; Vučetić M; Parks SK; Pouyssegur J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375025
[TBL] [Abstract][Full Text] [Related]
44. The cochaperone BAG3 coordinates protein synthesis and autophagy under mechanical strain through spatial regulation of mTORC1.
Kathage B; Gehlert S; Ulbricht A; Lüdecke L; Tapia VE; Orfanos Z; Wenzel D; Bloch W; Volkmer R; Fleischmann BK; Fürst DO; Höhfeld J
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):62-75. PubMed ID: 27756573
[TBL] [Abstract][Full Text] [Related]
45. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
46. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
47. The tuberous sclerosis complex: balancing proliferation and survival.
Tomasoni R; Mondino A
Biochem Soc Trans; 2011 Apr; 39(2):466-71. PubMed ID: 21428921
[TBL] [Abstract][Full Text] [Related]
48. TrkB hyperactivity contributes to brain dysconnectivity, epileptogenesis, and anxiety in zebrafish model of Tuberous Sclerosis Complex.
Kedra M; Banasiak K; Kisielewska K; Wolinska-Niziol L; Jaworski J; Zmorzynska J
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2170-2179. PubMed ID: 31932427
[TBL] [Abstract][Full Text] [Related]
49. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
[TBL] [Abstract][Full Text] [Related]
50. mTORC1 Is Not Principally Involved in the Induction of Human Endotoxin Tolerance.
Ludwig K; Husain RA; Rubio I
Front Immunol; 2020; 11():1515. PubMed ID: 32849516
[TBL] [Abstract][Full Text] [Related]
51. Endothelial deletion of mTORC1 protects against hindlimb ischemia in diabetic mice via activation of autophagy, attenuation of oxidative stress and alleviation of inflammation.
Fan W; Han D; Sun Z; Ma S; Gao L; Chen J; Li X; Li X; Fan M; Li C; Hu D; Wang Y; Cao F
Free Radic Biol Med; 2017 Jul; 108():725-740. PubMed ID: 28473248
[TBL] [Abstract][Full Text] [Related]
52. Autophagic lipid metabolism sustains mTORC1 activity in TSC-deficient neural stem cells.
Wang C; Haas MA; Yang F; Yeo S; Okamoto T; Chen S; Wen J; Sarma P; Plas DR; Guan JL
Nat Metab; 2019 Nov; 1(11):1127-1140. PubMed ID: 32577608
[TBL] [Abstract][Full Text] [Related]
53. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
54. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of ERK1/2 Restores GSK3β Activity and Protein Synthesis Levels in a Model of Tuberous Sclerosis.
Pal R; Bondar VV; Adamski CJ; Rodney GG; Sardiello M
Sci Rep; 2017 Jun; 7(1):4174. PubMed ID: 28646232
[TBL] [Abstract][Full Text] [Related]
56. TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.
Magini A; Polchi A; Di Meo D; Mariucci G; Sagini K; De Marco F; Cassano T; Giovagnoli S; Dolcetta D; Emiliani C
Hum Mol Genet; 2017 Sep; 26(17):3303-3312. PubMed ID: 28637240
[TBL] [Abstract][Full Text] [Related]
57. A genetic model to dissect the role of Tsc-mTORC1 in neuronal cultures.
Nie D; Sahin M
Methods Mol Biol; 2012; 821():393-405. PubMed ID: 22125080
[TBL] [Abstract][Full Text] [Related]
58. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.
Guo P; Ma X; Zhao W; Huai W; Li T; Qiu Y; Zhang Y; Han L
Oncogene; 2018 Jan; 37(4):478-488. PubMed ID: 28967907
[TBL] [Abstract][Full Text] [Related]
59. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).
Kwiatkowski DJ
Lymphat Res Biol; 2010 Mar; 8(1):51-7. PubMed ID: 20235887
[TBL] [Abstract][Full Text] [Related]
60. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
